Trial shows promise for Eli Lilly-developed breast cancer treatment
Eli Lilly and Company’s phase 3 monarchE trial of their cancer treatment drug Verzenio® (abemaciclib) has demonstrated a significant decrease risk of breast cancer recurrence for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) high risk early breast cancer. Read More »